5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Embryo-Fetal O
Toxicity O
. O

Do O
not O
use O
in O
pregnant O
women O
. O

Obtain O
a O
urine O
or O
serum O
pregnancy O
test O
prior O
to O
initiation O
of O
therapy O
. O

Advise O
use O
of O
effective O
contraception O
in O
females O
of O
reproductive O
potential O
( O
Boxed O
Warning O
, O
5.1 O
, O
8.1 O
, O
8.8 O
, O
13.1 O
) O
. O

* O
Reproductive O
effects O
. O

Miltefosine O
caused O
testicular O
atrophy O
and O
impaired O
fertility O
in O
male O
rats O
and O
impaired O
fertility O
in O
female O
rats O
. O

Advise O
patients O
of O
reproductive O
toxicities O
in O
animal O
studies O
and O
that O
the O
potential O
effects O
on O
human O
fertility O
have O
not O
been O
adequately O
evaluated O
( O
13.1 O
) O
. O

* O
Renal O
Effects O
. O

Monitor O
serum O
creatinine O
during O
therapy O
and O
for O
4 O
weeks O
after O
end O
of O
therapy O
( O
5.3 O
, O
6.1 O
) O
. O

* O
Hepatic O
Effects O
. O

Monitor O
transaminases O
and O
bilirubin O
during O
therapy O
( O
5.4 O
, O
6.1 O
) O
. O

* O
Gastrointestinal O
Effects O
. O

Encourage O
fluid O
intake O
( O
5.5 O
) O
. O

* O
Thrombocytopenia O
. O

Monitor O
platelet O
count O
during O
therapy O
for O
visceral O
leishmaniasis O
( O
5.6 O
, O
6.1 O
) O
. O

* O
Absorption O
of O
Oral O
Contraceptives O
. O

Advise O
use O
of O
alternative O
method O
of O
contraception O
if O
vomiting O
and/or O
diarrhea O
occur O
( O
5.7 O
) O
. O

* O
Stevens-Johnson O
syndrome O
. O

Discontinue O
IMPAVIDO O
( O
5.8 O
) O
. O

5.1 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Miltefosine O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
. O

Embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxicity I-NonOSE_AE
, O
including O
death O
and O
teratogenicity B-NonOSE_AE
, O
was O
observed O
in O
animals O
administered O
miltefosine O
prior O
to O
mating O
, O
during O
early O
pregnancy B-NonOSE_AE
, O
and O
during O
organogenesis O
at O
doses O
lower O
than O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
. O

Do O
not O
use O
IMPAVIDO O
in O
pregnant B-Not_AE_Candidate
women O
. O

Obtain O
a O
urine O
or O
serum O
pregnancy B-NonOSE_AE
test O
prior O
to O
prescribing O
IMPAVIDO O
to O
females O
of O
reproductive O
potential O
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
IMPAVIDO O
therapy O
and O
for O
5 O
months O
after O
completion O
of O
therapy O
[ O
see O
Boxed O
Warning O
, O
Contraindications O
( O
4.1 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.8 O
) O
] O
. O

5.2 O
Reproductive O
Effects O
Females O
Miltefosine O
caused O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
in O
rats O
and O
reversible B-NonOSE_AE
follicular I-NonOSE_AE
atresia I-NonOSE_AE
and O
diestrus B-NonOSE_AE
in O
dogs O
at O
doses O
approximately O
1.0 O
and O
0.2 O
times O
respectively O
the O
MRHD O
based O
on O
body O
surface O
area O
comparisons O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Effects O
on O
human O
female O
fertility O
have O
not O
been O
formally O
studied O
. O

Males O
Miltefosine O
caused O
reduced B-NonOSE_AE
viable O
sperm I-NonOSE_AE
counts I-NonOSE_AE
and O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
in O
rats O
at O
doses O
approximately O
0.4 O
times O
the O
MRHD O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

A O
higher O
dose O
in O
rats O
, O
approximately O
1.0 O
times O
the O
MRHD O
, O
caused O
testicular B-NonOSE_AE
atrophy I-NonOSE_AE
and O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
that O
did O
not O
fully O
reverse O
10 O
weeks O
after O
drug O
administration O
ended O
. O

Scrotal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
decreased B-OSE_Labeled_AE
or O
absent O
ejaculation I-OSE_Labeled_AE
during O
therapy O
have O
been O
reported O
during O
IMPAVIDO O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

The O
effects O
of O
IMPAVIDO O
on O
human O
male O
fertility O
have O
not O
been O
adequately O
studied O
. O

Advise O
women O
and O
men O
of O
the O
animal O
fertility O
findings O
, O
and O
that O
the O
potential O
for O
impaired B-NonOSE_AE
fertility I-NonOSE_AE
with O
IMPAVIDO O
therapy O
in O
humans O
has O
not O
been O
adequately O
evaluated O
. O

5.3 O
Renal O
Effects O
Elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
( I-OSE_Labeled_AE
Cr I-OSE_Labeled_AE
) O
were O
noted O
in O
clinical O
trials O
evaluating O
IMPAVIDO O
in O
the O
treatment O
of O
cutaneous B-Not_AE_Candidate
, I-Not_AE_Candidate
mucosal I-Not_AE_Candidate
and I-Not_AE_Candidate
visceral I-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
renal O
function O
weekly O
in O
patients O
receiving O
IMPAVIDO O
during O
therapy O
and O
for O
4 O
weeks O
after O
end O
of O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.4 O
Hepatic O
Effects O
Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
( O
ALT O
, O
AST O
) O
and O
bilirubin O
were O
noted O
in O
clinical O
trials O
evaluating O
IMPAVIDO O
in O
the O
treatment O
of O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
liver O
transaminases O
( O
ALT O
, O
AST O
) O
and O
bilirubin O
during O
therapy O
in O
patients O
receiving O
IMPAVIDO O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.5 O
Gastrointestinal O
Effects O
Vomiting B-OSE_Labeled_AE
and/or O
diarrhea B-OSE_Labeled_AE
commonly O
occur O
during O
IMPAVIDO O
administration O
and O
may O
result O
in O
volume B-NonOSE_AE
depletion I-NonOSE_AE
. O

Encourage O
fluid O
intake O
to O
avoid O
volume B-NonOSE_AE
depletion I-NonOSE_AE
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.6 O
Thrombocytopenia O
Thrombocytopenia B-OSE_Labeled_AE
during O
therapy O
has O
been O
reported O
in O
patients O
treated O
for O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
. O

Monitor O
platelet O
count O
during O
therapy O
for O
visceral B-Not_AE_Candidate
leishmaniasis I-Not_AE_Candidate
[ O
see O
Adverse O
Reactions O
( O
6.1 O
, O
6.2 O
) O
] O
. O

5.7 O
Absorption O
of O
Oral O
Contraceptives O
Vomiting B-NonOSE_AE
and/or O
diarrhea B-NonOSE_AE
occurring O
during O
IMPAVIDO O
therapy O
may O
affect O
the O
absorption O
of O
oral O
contraceptives O
, O
and O
therefore O
compromise O
their O
efficacy O
. O

If O
vomiting B-NonOSE_AE
and/or O
diarrhea B-NonOSE_AE
occur O
during O
IMPAVIDO O
therapy O
, O
advise O
females O
to O
use O
additional O
non-hormonal O
or O
alternative O
method O
( O
s O
) O
of O
effective O
contraception O
. O

5.8 O
Stevens-Johnson O
Syndrome O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
during O
IMPAVIDO O
therapy O
. O

Discontinue O
IMPAVIDO O
if O
an O
exfoliative B-NonOSE_AE
or O
bullous O
rash I-NonOSE_AE
is O
noted O
during O
therapy O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

